Home › Companies › Crescent Biopharma, Inc. › 2025-2026
At Crescent Biopharma, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 55 asset managers reported how they voted in their SEC Form N-PX filings, covering 236 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of Crescent Biopharma, Inc. 's… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Crescent Biopharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Crescent Biopharma, Inc.’s Form 8-K, filed June 3, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 2, 2026: 4 items on Crescent Biopharma, Inc.’s Form 8-K, filed June 3, 2026: 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2025-2026
Explore Crescent Biopharma, Inc. in the interactive database Compare manager voting policies
These tallies are Crescent Biopharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jonathan Violin, Ph.D. (Proposal No. 1A) | 2,890,000 | -- | -- | 0 | 0 | 100% | Not verified | — |
| Elect Director: Susan Moran, M.D., MSCE (Proposal No. 1B) | 21,401,136 | -- | -- | 136,056 | 2,403,515 | 99.3% | Not verified | — |
| 2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 21,049,101 | 1,452 | 154 | -- | 0 | 99.9% | Not verified | — |
| 3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers | 18,346,099 | 300,217 | 876 | -- | 2,403,515 | 98% | Not verified | — |
Source: Crescent Biopharma, Inc., Form 8-K, filed with the SEC on June 3, 2026 — read the filing on EDGAR.
Each item below shows how the 55 asset managers that disclosed a Crescent Biopharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Crescent Biopharma, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF CLASS II DIRECTOR FOR TERM EXPIRING AT THE 2029 ANNUAL GENERAL MEETING OF SHAREHOLDERS OR UNTIL THEIR SUCCESSOR IS DULY ELECTED AND QUALIFIED OR UNTIL THEIR EARLIER DEATH, RESIGNATION, DISQUALIFICATION OR REMOVAL: SUSAN MORAN, M.D., MSCE
Crescent Biopharma, Inc.’s own tally for this item (“Elect Director: Susan Moran, M.D., MSCE (Proposal No. 1B)”): 21,401,136 for, 136,056 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 3,344,323 for, 86,838 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,801,342 | 0 | 0 | 86,838 | For |
| Vanguard | 312,987 | 0 | 0 | 0 | For |
| T. Rowe Price | 213,851 | 0 | 0 | 0 | For |
| John Hancock | 6,199 | 0 | 0 | 0 | For |
| American Century | 5,576 | 0 | 0 | 0 | For |
| Victory Capital | 2,240 | 0 | 0 | 0 | For |
| Equitable | 1,814 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 114 | 0 | 0 | 0 | For |
Combines 6 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of Crescent Biopharma, Inc. 's named executive officers.
Crescent Biopharma, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers”): 18,346,099 for, 300,217 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,888,180 | 0 | 0 | 0 | For |
| Vanguard | 312,820 | 167 | 0 | 0 | For |
| T. Rowe Price | 213,851 | 0 | 0 | 0 | For |
| John Hancock | 6,199 | 0 | 0 | 0 | For |
| American Century | 5,576 | 0 | 0 | 0 | For |
| Victory Capital | 2,240 | 0 | 0 | 0 | For |
| Equitable | 1,814 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 114 | 0 | 0 | Against |
Fund voting reports, all 9 managers: 3,430,880 for, 281 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,100,704 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 2,747,866 | 0 | 0 | 0 | For |
| FCPM III SERVICES B.V. | 1,677,852 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 1,387,864 | 0 | 0 | 0 | For |
| BVF INC/IL | 1,387,863 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 440,342 | 0 | 0 | 0 | For |
| Point72 | 300,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 276,106 | 0 | 0 | 0 | For |
| Boxer Capital Management, LLC | 226,843 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 206,942 | 0 | 0 | 0 | For |
| Exome Asset Management LLC | 153,191 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 126,160 | 0 | 0 | Against |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 107,685 | 0 | 0 | Against |
| Vestal Point Capital, LP | 104,136 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 102,374 | 0 | 0 | 0 | For |
| BlackRock | 88,061 | 0 | 0 | 0 | For |
| Two Sigma | 84,438 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 80,998 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 0 | 38,228 | 0 | 0 | Against |
| Vanguard | 31,900 | 0 | 0 | 0 | For |
| Lighthouse Investment Partners, LLC | 0 | 25,000 | 0 | 0 | Against |
| Hudson Bay Capital Management LP | 22,927 | 0 | 0 | 0 | For |
| Northern Trust | 17,209 | 0 | 0 | 0 | For |
| State Street | 16,060 | 0 | 0 | 0 | For |
| American Century | 5,576 | 0 | 0 | 0 | For |
Institutional-manager reports, all 49 managers: 13,471,197 for, 298,590 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To vote, on a non-binding advisory basis, on the frequency of future advisory votes to approve compensation for Crescent Biopharma, Inc.'s named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 0 | -- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 9 managers: 3,431,160 1 year, 1 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Fairmount Funds Management LLC | 0 | 0 | 0 | 0 | -- |
| Venrock Adviser, LLC | 0 | 0 | 0 | 0 | -- |
| BVF INC/IL | 0 | 0 | 0 | 0 | -- |
| Deep Track Capital, LP | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Lighthouse Investment Partners, LLC | 0 | 0 | 0 | 0 | -- |
| Boxer Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| PERCEPTIVE ADVISORS LLC | 206,942 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 0 | 0 | 0 | -- |
| Vestal Point Capital, LP | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| JENNISON ASSOCIATES LLC | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Hudson Bay Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| Renaissance | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| BLAIR WILLIAM & CO/IL | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 44 managers: 206,942 for, 11,874,696 1 year, 52 3 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Crescent Biopharma, Inc. for its fiscal year ending December 31, 2026.
Crescent Biopharma, Inc.’s own tally for this item (“2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 21,049,101 for, 1,452 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 3,431,161 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,888,180 | 0 | 0 | 0 | For |
| Vanguard | 312,987 | 0 | 0 | 0 | For |
| T. Rowe Price | 213,851 | 0 | 0 | 0 | For |
| John Hancock | 6,199 | 0 | 0 | 0 | For |
| American Century | 5,576 | 0 | 0 | 0 | For |
| Victory Capital | 2,240 | 0 | 0 | 0 | For |
| Equitable | 1,814 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 114 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 27,571,935 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 10.48% |
| 2 | Vanguard | 1.14% |
| 3 | T. Rowe Price | 0.78% |
| 4 | John Hancock | 0.02% |
| 5 | American Century | 0.02% |
| 6 | Victory Capital | <0.01% |
| 7 | Equitable | <0.01% |
| 8 | Blackstone Alternative Investment Funds | <0.01% |
| 9 | Advisors' Inner Circle Fund III | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.87% |
| 2 | Fairmount Funds Management LLC | 9.97% |
| 3 | FCPM III SERVICES B.V. | 6.09% |
| 4 | Venrock Adviser, LLC | 5.03% |
| 5 | BVF INC/IL | 5.03% |
| 6 | Deep Track Capital, LP | 1.60% |
| 7 | Point72 | 1.09% |
| 8 | T. Rowe Price | 1.00% |
| 9 | Boxer Capital Management, LLC | 0.82% |
| 10 | PERCEPTIVE ADVISORS LLC | 0.75% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Fairmount Funds Management LLC | — | 13D |
| Peter Harwin | — | DEF14A |
| Entities affiliated with Fairmount Funds Management LLC | — | DEF14A |
| Entities affiliated with FMR LLC | — | DEF14A |
| FMR (Fidelity) | — | 13F |
| FMR LLC | — | 13G |
| Entities affiliated with BVF Partners L.P. | — | DEF14A |
| Entities affiliated with Venrock Healthcare Capital Partners | — | DEF14A |
| Venrock Healthcare Capital Partners III, L.P. | — | 13G |
| ForGrowth III PA B.V. | — | DEF14A |
Percentages above are of 27,571,935 shares outstanding, as reported by Crescent Biopharma, Inc. on its Form 10-Q dated April 24, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Crescent Biopharma, Inc.’s 10-Q dated April 24, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Crescent Biopharma, Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).
proxyvotesnow.com, “Crescent Biopharma (CBIO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/crescent-biopharma-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.